Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C27H27F2N5O3 |
| Molecular Weight | 507.5318 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(CCOC1=C(N)N=CN=C1C2=CC(F)=CC(NC(=O)C3=CC=C(C=C3F)C4CC4)=C2C)C(=O)C=C
InChI
InChIKey=CUABMPOJOBCXJI-UHFFFAOYSA-N
InChI=1S/C27H27F2N5O3/c1-4-23(35)34(3)9-10-37-25-24(31-14-32-26(25)30)20-12-18(28)13-22(15(20)2)33-27(36)19-8-7-17(11-21(19)29)16-5-6-16/h4,7-8,11-14,16H,1,5-6,9-10H2,2-3H3,(H,33,36)(H2,30,31,32)
| Molecular Formula | C27H27F2N5O3 |
| Molecular Weight | 507.5318 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
187 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
REMIBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
233 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
REMIBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
518 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
REMIBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
551 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
REMIBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
550 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
REMIBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
563 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
600 mg 1 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
REMIBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
180 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
REMIBRUTINIB blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
306 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
REMIBRUTINIB blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
236 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
200 mg 2 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
REMIBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
347 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
200 mg 2 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
REMIBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
315 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
REMIBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
485 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
REMIBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
977 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
REMIBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1280 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
REMIBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1080 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
REMIBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1230 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
600 mg 1 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
REMIBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
337 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
REMIBRUTINIB blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
496 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
REMIBRUTINIB blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
464 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
200 mg 2 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
REMIBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
963 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
200 mg 2 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
REMIBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.41 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
REMIBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
8.51 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
400 mg 1 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
REMIBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
8.29 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
600 mg 1 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
REMIBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.84 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
REMIBRUTINIB blood | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
12.4 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/33834628/ |
200 mg 2 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
REMIBRUTINIB plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 19:16:44 GMT 2025
by
admin
on
Tue Apr 01 19:16:44 GMT 2025
|
| Record UNII |
I7MVZ8HDNU
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
JK-247
Created by
admin on Tue Apr 01 19:16:44 GMT 2025 , Edited by admin on Tue Apr 01 19:16:44 GMT 2025
|
PRIMARY | |||
|
11062
Created by
admin on Tue Apr 01 19:16:44 GMT 2025 , Edited by admin on Tue Apr 01 19:16:44 GMT 2025
|
PRIMARY | |||
|
I7MVZ8HDNU
Created by
admin on Tue Apr 01 19:16:44 GMT 2025 , Edited by admin on Tue Apr 01 19:16:44 GMT 2025
|
PRIMARY | |||
|
C175851
Created by
admin on Tue Apr 01 19:16:44 GMT 2025 , Edited by admin on Tue Apr 01 19:16:44 GMT 2025
|
PRIMARY | |||
|
1787294-07-8
Created by
admin on Tue Apr 01 19:16:44 GMT 2025 , Edited by admin on Tue Apr 01 19:16:44 GMT 2025
|
PRIMARY | |||
|
118107483
Created by
admin on Tue Apr 01 19:16:44 GMT 2025 , Edited by admin on Tue Apr 01 19:16:44 GMT 2025
|
PRIMARY | |||
|
300000010835
Created by
admin on Tue Apr 01 19:16:44 GMT 2025 , Edited by admin on Tue Apr 01 19:16:44 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
|
TRANSPORTER -> SUBSTRATE |
|
||
|
|
METABOLIC ENZYME -> INHIBITOR |
|
||
|
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
